EUVIMEDEUVIMED entdecken
Klinische Studie

Risk Reduction by Direct Thrombin Antagonism During ECMO Therapy

Susanne Rohrbach, Maurice Himmel, Melanie Spaenig, Andreas Böning, Florian Brenck, Michael Sander, Joern Pons-Kuehnemann, Thomas Walther, Bernd Niemann iD

The Thoracic and Cardiovascular Surgeon · 01.10.2026 · 74 (07) · 577-587

DOI: 10.1055/a-2851-6221 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift The Thoracic and Cardiovascular Surgeon, erschienen am 01.10.2026. Verfasst von Susanne Rohrbach und 8 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Physiology, Justus-Liebig-Universitat Giessen, Giessen, Hessen, Germany. Die Arbeit nennt 28 Literaturangaben. Gefördert von: Mitsubishi Pharma.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ECMO patients can develop heparin (Hep)-induced thrombocytopenia type II (HIT II). Approval for direct thrombin antagonism is lacking. We analyze if direct thrombin antagonism (DTA) is feasible, safe, and not inferior to heparin. A total of 254 multicenter prospective patients (vv- or va-ECMO) were analyzed in four different cardiothoracic, pulmonary, or anesthesiological intensive care units at university hospitals in Giessen and Frankfurt from 2020 to 2022. Heparin was always received by 153 va-ECMO/101 vv-ECMO patients (95/43), only DTA (8/6) or a switch (50/52) from heparin to DTA in cases of suspected HITII and reduced platelet count (reduction: p = 0.017). ICU morbidity, survival, therapeutic stability of anticoagulation, bleeding, thrombosis, and technical integrity were analyzed regarding noninferiority and superiority of DTA versus heparin. Patients who changed anticoagulation showed increased infection levels before the change. Before switching from heparin to DTA, there was only a moderate increase in the INR, a decrease in the Quick, and no therapeutic increase in the PTT with heparin. With regard to thrombosis and system occlusions, there is no difference between heparin and DTA. Weaning rates from extracorporeal support and survival analysis did show noninferiority of DTA. After switching, a clear superiority of DTA in terms of (A) overall complication rate CI((0.6479/0.7871/0.9546)) (defined as bleeding from any cause, stroke, amputation, thrombosis and device-occlusion) and (B) bleeding from any cause alone CI((0.6432/0.7829/0.9513)) and a noninferiority in terms of preventing strokes exists. DTA is not inferior to heparin in ECLS/ECMO therapy. Regarding all complications, stroke, thromboembolism, and amputation DTA is superior.

Autor:innen und Institutionen

  • Institute of Physiology, Justus-Liebig-Universitat Giessen, Giessen, Hessen, Germany.
  • Department for Adult and Pediatric Cardiac and Vascular Surgery, University Hospital Giessen and Marburg, Giessen, Hessen, Germany.
  • Department of Cardiovascular Surgery, University Hospital Giessen, Giessen, Germany.
  • Department for Anesthesiology and Intensive Care Medicine, University Hospital Giessen and Marburg, Giessen, Hessen, Germany.
  • Institute for Medical Informatics and Statistics, University Hospital Giessen, Giessen, Hessen, Germany.
  • Department of Cardiovascular Surgery, University Hospital Frankfurt, Frankfurt, Germany.

ORCID-Profile: Bernd Niemann

Förderung

  • Mitsubishi Pharma

Zitieren

APA

Rohrbach, S., Himmel, M., Spaenig, M., Böning, A., Brenck, F., Sander, M., Pons-Kuehnemann, J., Walther, T., & Niemann, B. (2026). Risk Reduction by Direct Thrombin Antagonism During ECMO Therapy. The Thoracic and Cardiovascular Surgeon, 74(07), 577-587. https://doi.org/10.1055/a-2851-6221

Vancouver

Rohrbach S, Himmel M, Spaenig M, Böning A, Brenck F, Sander M, et al. Risk Reduction by Direct Thrombin Antagonism During ECMO Therapy. The Thoracic and Cardiovascular Surgeon. 2026;74(07):577-587. doi:10.1055/a-2851-6221

BibTeX
@article{Rohrbach2026,
  author = {Rohrbach, Susanne and Himmel, Maurice and Spaenig, Melanie and Böning, Andreas and Brenck, Florian and Sander, Michael and Pons-Kuehnemann, Joern and Walther, Thomas and Niemann, Bernd},
  title = {Risk Reduction by Direct Thrombin Antagonism During ECMO Therapy},
  journal = {The Thoracic and Cardiovascular Surgeon},
  year = {2026},
  volume = {74},
  number = {07},
  pages = {577--587},
  doi = {10.1055/a-2851-6221}
}
Kostenlos starten →